Envestnet Asset Management Inc. Acquires 54,105 Shares of DexCom, Inc. (NASDAQ:DXCM)

Envestnet Asset Management Inc. raised its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 9.3% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 638,170 shares of the medical device company's stock after buying an additional 54,105 shares during the period. Envestnet Asset Management Inc. owned about 0.16% of DexCom worth $43,581,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of DXCM. Golden State Wealth Management LLC grew its position in shares of DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after purchasing an additional 264 shares during the last quarter. Optiver Holding B.V. acquired a new position in shares of DexCom in the fourth quarter valued at approximately $33,000. TD Private Client Wealth LLC grew its position in shares of DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares during the last quarter. Heck Capital Advisors LLC acquired a new position in shares of DexCom in the fourth quarter valued at approximately $38,000. Finally, Alpine Bank Wealth Management acquired a new position in shares of DexCom in the first quarter valued at approximately $40,000. Institutional investors own 97.75% of the company's stock.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 10,000 shares of the firm's stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $84.28, for a total transaction of $842,800.00. Following the completion of the transaction, the executive vice president directly owned 95,602 shares of the company's stock, valued at $8,057,336.56. This trade represents a 9.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Sadie Stern sold 6,184 shares of the firm's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total value of $526,320.24. Following the transaction, the executive vice president directly owned 109,621 shares of the company's stock, valued at approximately $9,329,843.31. This represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 27,190 shares of company stock valued at $2,281,732 in the last quarter. 0.32% of the stock is currently owned by company insiders.

DexCom Price Performance

Shares of DXCM traded down $2.09 during trading hours on Friday, reaching $83.37. The stock had a trading volume of 2,309,390 shares, compared to its average volume of 4,433,737. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $117.19. The stock has a market capitalization of $32.69 billion, a PE ratio of 62.22, a PEG ratio of 1.78 and a beta of 1.44. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. The company's 50-day moving average is $84.35 and its two-hundred day moving average is $79.99.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the previous year, the company posted $0.32 earnings per share. The firm's revenue was up 12.5% on a year-over-year basis. Research analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

DXCM has been the topic of several research reports. Piper Sandler decreased their target price on DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Canaccord Genuity Group increased their price target on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Truist Financial started coverage on DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 price target on the stock. The Goldman Sachs Group started coverage on DexCom in a research report on Friday, May 30th. They set a "buy" rating and a $104.00 price target on the stock. Finally, Cfra Research raised DexCom to a "hold" rating in a research report on Friday, March 21st. Five research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $98.50.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.